These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 37166552)
21. Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection. Bremell D; Mattsson N; Edsbagge M; Blennow K; Andreasson U; Wikkelsö C; Zetterberg H; Hagberg L BMC Neurol; 2013 Jan; 13():2. PubMed ID: 23294475 [TBL] [Abstract][Full Text] [Related]
22. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch. Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471 [TBL] [Abstract][Full Text] [Related]
23. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. Gisslén M; Fuchs D; Svennerholm B; Hagberg L J Acquir Immune Defic Syndr; 1999 Aug; 21(4):271-6. PubMed ID: 10428104 [TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study. Yilmaz A; Fuchs D; Hagberg L; Nillroth U; Ståhle L; Svensson JO; Gisslén M BMC Infect Dis; 2006 Mar; 6():63. PubMed ID: 16566834 [TBL] [Abstract][Full Text] [Related]
25. IgG intrathecal synthesis in HIV-associated neurocognitive disorder (HAND) according to the HIV-1 subtypes and pattern of HIV RNA in CNS and plasma compartments. De Almeida SM; Rotta I; Tang B; Vaida F; Letendre S; Ellis RJ; J Neuroimmunol; 2021 Jun; 355():577542. PubMed ID: 33845284 [TBL] [Abstract][Full Text] [Related]
26. Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study. Jespersen S; Pedersen KK; Anesten B; Zetterberg H; Fuchs D; Gisslén M; Hagberg L; Trøseid M; Nielsen SD BMC Infect Dis; 2016 Apr; 16():176. PubMed ID: 27103116 [TBL] [Abstract][Full Text] [Related]
27. Beyond T cell toxicity - Intrathecal chemokine CXCL13 indicating B cell involvement in immune-related adverse events following checkpoint inhibition: A two-case series and literature review. Otto F; Seiberl M; Bieler L; Moser T; Kleindienst W; Wallner-Essl W; Koelblinger P; Wipfler P; Harrer A Eur J Neurol; 2024 Jul; 31(7):e16279. PubMed ID: 38556899 [TBL] [Abstract][Full Text] [Related]
29. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. Dahl V; Peterson J; Fuchs D; Gisslen M; Palmer S; Price RW AIDS; 2014 Sep; 28(15):2251-8. PubMed ID: 25022595 [TBL] [Abstract][Full Text] [Related]
30. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment. Ulfhammer G; Edén A; Mellgren Å; Fuchs D; Zetterberg H; Hagberg L; Nilsson S; Yilmaz A; Gisslén M AIDS; 2018 Sep; 32(15):2171-2178. PubMed ID: 30005007 [TBL] [Abstract][Full Text] [Related]
31. Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen. Stroffolini G; Lazzaro A; Barco A; Pirriatore V; Vai D; Giaccone C; Nigra M; Atzori C; Trunfio M; Bonora S; Di Perri G G; Calcagno A J Neuroimmune Pharmacol; 2023 Dec; 18(4):551-562. PubMed ID: 37906406 [TBL] [Abstract][Full Text] [Related]
34. Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection. Pérez-Santiago J; Schrier RD; de Oliveira MF; Gianella S; Var SR; Day TR; Ramirez-Gaona M; Suben JD; Murrell B; Massanella M; Cherner M; Smith DM; Ellis RJ; Letendre SL; Mehta SR J Neurovirol; 2016 Apr; 22(2):191-200. PubMed ID: 26428514 [TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection. Hermansson L; Yilmaz A; Axelsson M; Blennow K; Fuchs D; Hagberg L; Lycke J; Zetterberg H; Gisslén M J Neuroinflammation; 2019 Jan; 16(1):16. PubMed ID: 30678707 [TBL] [Abstract][Full Text] [Related]
36. Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection. Suh J; Sinclair E; Peterson J; Lee E; Kyriakides TC; Li FY; Hagberg L; Fuchs D; Price RW; Gisslen M; Spudich S J Neuroinflammation; 2014 Dec; 11():199. PubMed ID: 25465205 [TBL] [Abstract][Full Text] [Related]
37. Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers. Caligaris G; Trunfio M; Ghisetti V; Cusato J; Nigra M; Atzori C; Imperiale D; Bonora S; Di Perri G; Calcagno A Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34065785 [TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy. Guha D; Mukerji SS; Chettimada S; Misra V; Lorenz DR; Morgello S; Gabuzda D AIDS; 2019 Mar; 33(4):615-625. PubMed ID: 30557159 [TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. Bielekova B; Komori M; Xu Q; Reich DS; Wu T PLoS One; 2012; 7(11):e48370. PubMed ID: 23226202 [TBL] [Abstract][Full Text] [Related]